ClinicalTrials.gg
CompletedNCT04186871Updated Jan 16, 2024Results posted

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

A Phase 2 interventional study of branebrutinib and abatacept in Autoimmune Disorder, Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb. Completed at 81 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-16.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 341 studies in Autoimmune Diseases with a site in United States — 91 open to participants now, 117 under way, 19 of them phase 3. Autoimmune Diseases · United States.

Enrollment
71st of 243
119 · median 53
Started
2020
with 16 others
Phase 2
75 of 341
13 open now
Registered
206th of 341
by date

Among the 341 studies in Autoimmune Diseases with a site in United States, this one is the 71st largest by enrollment of the 243 interventional ones that give a count, is one of 17 that started in 2020, is one of 75 in phase 2, and was the 206th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

91 of the 341 studies in Autoimmune Diseases with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 341 studies in Autoimmune Diseases with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).

03

Conditions studied

  • Autoimmune Disorder
  • Rheumatoid Arthritis
  • Systemic Lupus Erythematosus
  • Primary Sjögren's Syndrome
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Sub-study for Systemic Lupus Erythematosus (SLE)

  • Active SLE as defined by the Systemic Lupus Erythematosus International Collaborating Clinics (SLICC) classification
  • Diagnosed with SLE more than 24 weeks before screening visit

Sub-study for primary Sjögren's Syndrome (pSS)

  • Moderate to severe pSS, meeting ACR-EULAR classification criteria

Sub-study for active Rheumatoid Arthritis (RA)

  • Moderate to severe adult-onset RA
  • ACR global functional status class I to III

Women and men must agree to follow instructions for methods of .

Exclusion criteria

Exclusion Criteria:

Sub-study for SLE

  • Certain other diseases and overlap syndromes

Sub-study for pSS

  • Certain other immune-mediated diseases, active fibromyalgia, or other medical conditions

Sub-study for RA

  • Diagnosis with juvenile arthritis or idiopathic arthritis before age 16

For all sub-studies:

  • History of any significant drug allergy
  • Active infection, significant concurrent medical condition, or abnormalities

Other protocol defined inclusion/exclusion criteria could apply

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    Systemic Lupus Erythematosus (SLE): branebrutinib

    Drug: branebrutinib

  • Placebo comparator
    SLE: placebo

    Drug: branebrutinib placebo

  • Experimental
    Primary Sjögren's Syndrome (pSS): branebrutinib

    Drug: branebrutinib

  • Placebo comparator
    pSS: placebo

    Drug: branebrutinib placebo

  • Experimental
    Rheumatoid Arthritis (RA): branebrutinib followed by abatacept

    Drug: branebrutinib · Drug: abatacept

  • Placebo comparator
    RA: placebo followed by abatacept

    Drug: abatacept · Drug: branebrutinib placebo

Interventions

  • Specified dose on specified days

  • Specified dose on specified days

  • Drugbranebrutinib placebo

    Specified dose on specified days

06

What researchers measure

Primary outcomes

  1. The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE

    mCLASI response is defined as a decrease of ≥ 50% from baseline mCLASI activity score, in participants with a baseline mCLASI activity score ≥ 10, at Week 24. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. To be considered as meeting the second criterion, the CS (prednisone or equivalent) dose had to remain stable and ≤ 10 mg from Week 16 until Week 24. The modified CLASI (mCLASI) is defined as the activity portions of CLASI that describe skin erythema and scale/hypertrophy and inflammation of the scalp. The percentage of patients who entered the study with a positive mCLASI activity score (≥ 10) and who achieved a ≥ 50% decrease from baseline at Week 24 is considered to likely represent a clinically meaningful improvement. The scores are calculated by simple addition based on the extent of the symptoms. mCLASI: Modified Cutaneous Lupus Erythematosus Disease Area and Severity Index

    Time frame: Week 24

  2. The Percent of Participants With Composite Response at Week 24 - pSS

    Composite response is defined as the percent of participants with at least 3 of the following at Week 24: * Decrease of ≥ 1 point or 15% from baseline in the ESSPRI Total Score * Decrease of ≥ 3 points from baseline in ESSDAI score * Decrease of ≥ 25% from baseline in ocular staining score, or if normal score at baseline no change to abnormal * Increase of ≥ 25% from baseline in stimulated salivary flow * Improvement in one or more serological markers (rheumatoid factor (RF), immunoglobulin G protein (IgG), complement C3 or C4, cryoglobulin).

    Time frame: Week 24

  3. Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA

    ACR50 response is defined as both improvement of 50% in the number of tender and swollen joints and a 50% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

    Time frame: Week 12

Secondary outcomes

  1. Change From Baseline in SLEDAI-2K Score at Week 24 - SLE

    The SLEDAI-2K is a global index providing a total score of overall disease activity ranging from 0 to 105, with higher scores representing more active disease. The SLEDAI index includes 24 items divided into 9 organ systems: neurological, musculoskeletal, renal, mucocutaneous, general, heart, respiratory, vascular, and hematological. Each item is scored based on the severity of the symptom or finding, with higher scores indicating more severe disease activity. The weighted scores for each item range from 0 to 8. To calculate the SLEDAI-2K score, the scores for each of the 24 items are added together. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

    Time frame: Week 24

  2. Percent of Participants With BICLA Response at Week 24 - SLE

    BILAG-based composite lupus assessment (BICLA) response is defined as: 1. At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry 2. No new BILAG A or more than one new BILAG B scores 3. No worsening of total SLEDAI score from baseline 4. No significant deterioration (\< 10%) in PGA and 5. No treatment failure (initiation of nonprotocol treatment). BILAG scores: A (severe disease), B (moderate), C (mild), or D (no activity). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

    Time frame: Week 24

  3. Change From Baseline in DAS28-CRP at Week 12 - RA

    The Disease Activity Score-28-C-Reactive Protein (DAS28CRP) is a composite outcome assessment that measures: 1) How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28, 2) CRP in the blood to measure the degree of inflammation, and 3) SGA of disease activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-CRP indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

    Time frame: Week 12

  4. Change From Baseline in DAS28-ESR at Week 12 - RA

    The Disease Activity Score Erythrocyte Sedimentation Rate - DAS28ESR is a composite outcome assessment that measures: 1. How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28 2. ESR in the blood to measure the degree of inflammation 3. SGA of disease activity DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-ESR score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-ESR indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

    Time frame: Week 12

  5. Change From Baseline in SDAI at Week 12- RA

    The Simplified Disease Activity Index (SDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the subject global assessment (SGA) of disease activity (range 0 to 10 in increments of 0.5), the PGA of disease activity (range 0 to 10 in increments of 0.5), and C-reactive protein (CRP) test result. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A SDAI score ranges from 0 (disease remission) to 86 (high disease activity).

    Time frame: Week 12

  6. Change From Baseline in CDAI at Week 12 - RA

    The Clinical Disease Activity Index (CDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the SGA of disease activity (range 0 to 10 in increments of 0.5), and the PGA of disease activity (range 0 to 10 in increments of 0.5). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A CDAI score ranges from 0 to 76. The interpretation of CDAI is as follows: 0.0 - 2.8: Disease remission 2.9 - 10.0: Low disease activity (LDA) 10.1 - 22.0: Moderate disease activity 22.1 - 76.0: High disease activity

    Time frame: Week 12

  7. Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA

    ACR20 defined as both improvement of 20% in the number of tender and swollen joints and a 20% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

    Time frame: Week 12

  8. Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA

    ACR70 is defined as both improvement of 70% in the number of tender and swollen joints and a 70% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

    Time frame: Week 12

07

Results

Posted Jan 16, 2024

Participant flow

Participant flow — Overall Study
MilestoneSLE- PlaceboSLE- BranebrutinibpSS- PlacebopSS- BranebrutinibRA- PlaceboRA- Branebrutinib
Started5154102164
Double blind period5154102164
Open label period00002061
Completed311492058
Not completed240116
Withdrew: Lack of efficacy010011
Withdrew: Adverse event110002
Withdrew: Study terminated by sponsor120100
Withdrew: Other reasons000001
Withdrew: Withdrawal by subject000001
Withdrew: Lost to follow-up000001

Outcome measures

PrimaryThe Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE

mCLASI response is defined as a decrease of ≥ 50% from baseline mCLASI activity score, in participants with a baseline mCLASI activity score ≥ 10, at Week 24. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. To be considered as meeting the second criterion, the CS (prednisone or equivalent) dose had to remain stable and ≤ 10 mg from Week 16 until Week 24. The modified CLASI (mCLASI) is defined as the activity portions of CLASI that describe skin erythema and scale/hypertrophy and inflammation of the scalp. The percentage of patients who entered the study with a positive mCLASI activity score (≥ 10) and who achieved a ≥ 50% decrease from baseline at Week 24 is considered to likely represent a clinically meaningful improvement. The scores are calculated by simple addition based on the extent of the symptoms. mCLASI: Modified Cutaneous Lupus Erythematosus Disease Area and Severity Index

Time frame:
Week 24
Reported as:
Number · Percentage of participants
The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE
Percentage of participantsSLE- PlaceboSLE- Branebrutinib
The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE60.0 (17.1 to 100)33.3 (9.5 to 57.2)
Statistical analysis
  • SLE- Placebo vs SLE- Branebrutinib · Response difference: -27.8 · 95% CI -77.5 to 21.9
  • SLE- Placebo vs SLE- Branebrutinib · Cochran-Mantel-Haenszel · p = 0.3117 · Odds ratio (or): 0.32 · 95% CI 0.04 to 2.73
SecondaryChange From Baseline in SLEDAI-2K Score at Week 24 - SLE

The SLEDAI-2K is a global index providing a total score of overall disease activity ranging from 0 to 105, with higher scores representing more active disease. The SLEDAI index includes 24 items divided into 9 organ systems: neurological, musculoskeletal, renal, mucocutaneous, general, heart, respiratory, vascular, and hematological. Each item is scored based on the severity of the symptom or finding, with higher scores indicating more severe disease activity. The weighted scores for each item range from 0 to 8. To calculate the SLEDAI-2K score, the scores for each of the 24 items are added together. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

Time frame:
Week 24
Reported as:
Mean · Change in "score on a scale"
Change From Baseline in SLEDAI-2K Score at Week 24 - SLE
Change in "score on a scale"SLE- PlaceboSLE- Branebrutinib
Change From Baseline in SLEDAI-2K Score at Week 24 - SLE-7.0 ± 5.29-7.0 ± 6.54
Statistical analysis
  • SLE- Placebo vs SLE- Branebrutinib · Mean difference (final values): 1.0 · 95% CI -2.8 to 4.9
  • SLE- Placebo · Mean difference (final values): -8.3 · 95% CI -11.5 to -5.0
  • SLE- Branebrutinib · Mean difference (final values): -7.2 · 95% CI -9.3 to -5.2
SecondaryPercent of Participants With BICLA Response at Week 24 - SLE

BILAG-based composite lupus assessment (BICLA) response is defined as: 1. At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry 2. No new BILAG A or more than one new BILAG B scores 3. No worsening of total SLEDAI score from baseline 4. No significant deterioration (\< 10%) in PGA and 5. No treatment failure (initiation of nonprotocol treatment). BILAG scores: A (severe disease), B (moderate), C (mild), or D (no activity). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

Time frame:
Week 24
Reported as:
Number · Percent of participants
Percent of Participants With BICLA Response at Week 24 - SLE
Percent of participantsSLE- PlaceboSLE- Branebrutinib
Percent of Participants With BICLA Response at Week 24 - SLE20.0 (0.5 to 71.6)33.3 (11.8 to 61.6)
Statistical analysis
  • SLE- Placebo vs SLE- Branebrutinib · Response difference: 16.7 · 95% CI -31.8 to 65.2
  • SLE- Placebo vs SLE- Branebrutinib · Odds ratio (or): 2.00 · 95% CI 0.22 to 18.04
PrimaryThe Percent of Participants With Composite Response at Week 24 - pSS

Composite response is defined as the percent of participants with at least 3 of the following at Week 24: * Decrease of ≥ 1 point or 15% from baseline in the ESSPRI Total Score * Decrease of ≥ 3 points from baseline in ESSDAI score * Decrease of ≥ 25% from baseline in ocular staining score, or if normal score at baseline no change to abnormal * Increase of ≥ 25% from baseline in stimulated salivary flow * Improvement in one or more serological markers (rheumatoid factor (RF), immunoglobulin G protein (IgG), complement C3 or C4, cryoglobulin).

Time frame:
Week 24
Reported as:
Number · Percent of Participants
The Percent of Participants With Composite Response at Week 24 - pSS
Percent of ParticipantspSS- PlacebopSS- Branebrutinib
The Percent of Participants With Composite Response at Week 24 - pSS25 (0.0 to 67.4)10 (0.0 to 28.6)
Statistical analysis
  • pSS- Placebo vs pSS- Branebrutinib · Response difference: -11.9 · 95% CI -57.1 to 33.3
  • pSS- Placebo vs pSS- Branebrutinib · Cochran-Mantel-Haenszel · p = 0.5930 · Odds ratio (or): 0.40 · 95% CI 0.02 to 10.02
PrimaryPercent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA

ACR50 response is defined as both improvement of 50% in the number of tender and swollen joints and a 50% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

Time frame:
Week 12
Reported as:
Number · Percent of Participants
Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA
Percent of ParticipantsRA- PlaceboRA- Branebrutinib
Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA33.3 (13.2 to 53.5)18.8 (9.2 to 28.3)
Statistical analysis
  • RA- Placebo vs RA- Branebrutinib · Response difference: -14.6 · 95% CI -36.9 to 7.7
  • RA- Placebo vs RA- Branebrutinib · Chi-squared · p = 0.1639 · Odds ratio (or): 0.46 · 95% CI 0.15 to 1.39
SecondaryChange From Baseline in DAS28-CRP at Week 12 - RA

The Disease Activity Score-28-C-Reactive Protein (DAS28CRP) is a composite outcome assessment that measures: 1) How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28, 2) CRP in the blood to measure the degree of inflammation, and 3) SGA of disease activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-CRP indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in DAS28-CRP at Week 12 - RA
Score on a scaleRA- PlaceboRA- Branebrutinib
Change From Baseline in DAS28-CRP at Week 12 - RA-1.615 ± 1.19545-1.542 ± 1.0790
Statistical analysis
  • RA- Placebo · Mean difference (final values): -1.610 · 95% CI -2.110 to -1.110
  • RA- Branebrutinib · Mean difference (final values): -1.567 · 95% CI -1.855 to -1.280
  • RA- Placebo vs RA- Branebrutinib · Mean difference (final values): 0.043 · 95% CI -0.534 to 0.620
SecondaryChange From Baseline in DAS28-ESR at Week 12 - RA

The Disease Activity Score Erythrocyte Sedimentation Rate - DAS28ESR is a composite outcome assessment that measures: 1. How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28 2. ESR in the blood to measure the degree of inflammation 3. SGA of disease activity DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-ESR score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-ESR indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in DAS28-ESR at Week 12 - RA
Score on a scaleRA- PlaceboRA- Branebrutinib
Change From Baseline in DAS28-ESR at Week 12 - RA-1.758 ± 1.1932-1.670 ± 1.1487
Statistical analysis
  • RA- Placebo · Mean difference (final values): -1.741 · 95% CI -2.256 to -1.226
  • RA- Branebrutinib · Mean difference (final values): -1.698 · 95% CI -1.998 to -1.399
  • RA- Placebo vs RA- Branebrutinib · Mean difference (final values): 0.043 · 95% CI -0.553 to 0.639
SecondaryChange From Baseline in SDAI at Week 12- RA

The Simplified Disease Activity Index (SDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the subject global assessment (SGA) of disease activity (range 0 to 10 in increments of 0.5), the PGA of disease activity (range 0 to 10 in increments of 0.5), and C-reactive protein (CRP) test result. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A SDAI score ranges from 0 (disease remission) to 86 (high disease activity).

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in SDAI at Week 12- RA
Score on a scaleRA- PlaceboRA- Branebrutinib
Change From Baseline in SDAI at Week 12- RA-19.430 ± 12.5890-18.303 ± 11.5793
Statistical analysis
  • RA- Placebo · Mean difference (final values): -19.495 · 95% CI -24.861 to -14.128
  • RA- Branebrutinib · Mean difference (final values): -18.767 · 95% CI -21.848 to -15.686
  • RA- Placebo vs RA- Branebrutinib · Mean difference (final values): 0.728 · 95% CI -5.463 to 6.919
SecondaryChange From Baseline in CDAI at Week 12 - RA

The Clinical Disease Activity Index (CDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the SGA of disease activity (range 0 to 10 in increments of 0.5), and the PGA of disease activity (range 0 to 10 in increments of 0.5). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A CDAI score ranges from 0 to 76. The interpretation of CDAI is as follows: 0.0 - 2.8: Disease remission 2.9 - 10.0: Low disease activity (LDA) 10.1 - 22.0: Moderate disease activity 22.1 - 76.0: High disease activity

Time frame:
Week 12
Reported as:
Mean · Score on a scale
Change From Baseline in CDAI at Week 12 - RA
Score on a scaleRA- PlaceboRA- Branebrutinib
Change From Baseline in CDAI at Week 12 - RA-19.4 ± 12.07-18.0 ± 11.01
Statistical analysis
  • RA- Placebo · Mean difference (final values): -19.2 · 95% CI -24.3 to -14.1
  • RA- Branebrutinib · Mean difference (final values): -18.5 · 95% CI -21.4 to -15.5
  • RA- Placebo vs RA- Branebrutinib · Mean difference (final values): 0.7 · 95% CI -5.2 to 6.6
SecondaryPercent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA

ACR20 defined as both improvement of 20% in the number of tender and swollen joints and a 20% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

Time frame:
Week 12
Reported as:
Number · Percent of Participants
Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA
Percent of ParticipantsRA- PlaceboRA- Branebrutinib
Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA61.9 (41.1 to 82.7)57.8 (45.7 to 69.9)
Statistical analysis
  • RA- Placebo vs RA- Branebrutinib · Response difference: -4.1 · 95% CI -28.1 to 19.9
  • RA- Placebo vs RA- Branebrutinib · Odds ratio (or): 0.84 · 95% CI 0.31 to 2.32
SecondaryPercent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA

ACR70 is defined as both improvement of 70% in the number of tender and swollen joints and a 70% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.

Time frame:
Week 12
Reported as:
Number · Percent of Participants
Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA
Percent of ParticipantsRA- PlaceboRA- Branebrutinib
Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA14.3 (0.0 to 29.3)7.8 (1.2 to 14.4)
Statistical analysis
  • RA- Placebo vs RA- Branebrutinib · Response difference: -6.5 · 95% CI -22.8 to 9.9
  • RA- Placebo vs RA- Branebrutinib · Odds ratio (or): 0.51 · 95% CI 0.11 to 2.34

Adverse events

Collected over All-cause mortality was assessed from participants first dose to their study completion (up to approximately 32 weeks) SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 30 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SLE- Placebo0/5 (0%)0/5 (0%)4/5 (80%)
SLE- Branebrutinib0/15 (0%)0/15 (0%)14/15 (93.3%)
pSS- Placebo0/4 (0%)0/4 (0%)4/4 (100%)
pSS- Branebrutinib0/10 (0%)0/10 (0%)8/10 (80%)
RA- Placebo0/21 (0%)0/21 (0%)6/21 (28.6%)
RA- Branebrutinib0/64 (0%)0/64 (0%)13/64 (20.3%)
RA Abatacept0/81 (0%)0/81 (0%)5/81 (6.2%)
Most frequent other events
Showing 10 of 44
Most frequent other events
EventSLE- PlaceboSLE- BranebrutinibpSS- PlacebopSS- BranebrutinibRA- PlaceboRA- BranebrutinibRA Abatacept
NasopharyngitisInfections and infestations0/52/153/42/101/211/641/81
NauseaGastrointestinal disorders0/50/151/40/100/210/640/81
DiscomfortGeneral disorders0/50/151/40/100/210/640/81
PyrexiaGeneral disorders0/50/151/40/100/210/640/81
SunburnInjury, poisoning and procedural complications0/51/151/40/100/210/640/81
BursitisMusculoskeletal and connective tissue disorders0/50/151/40/100/210/640/81
HeadacheNervous system disorders0/51/151/41/101/211/641/81
EnterocolitisGastrointestinal disorders1/50/150/40/100/210/640/81
GastritisGastrointestinal disorders1/50/150/40/100/210/640/81
AstheniaGeneral disorders1/50/150/40/100/211/640/81

Baseline characteristics

Age, Continuous
Age, Continuous(Years)SLE- PlaceboSLE- BranebrutinibpSS- PlacebopSS- BranebrutinibRA- PlaceboRA- BranebrutinibTotal
Mean47.6 ± 10.9944.2 ± 12.9147.8 ± 4.1946.6 ± 9.2846.0 ± 12.9550.1 ± 11.6248.2 ± 11.68
Sex: Female, Male
Sex: Female, Male(Participants)SLE- PlaceboSLE- BranebrutinibpSS- PlacebopSS- BranebrutinibRA- PlaceboRA- BranebrutinibTotal
Female51447184593
Male010331926
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SLE- PlaceboSLE- BranebrutinibpSS- PlacebopSS- BranebrutinibRA- PlaceboRA- BranebrutinibTotal
Hispanic or Latino39011721
Not Hispanic or Latino2648205797
Unknown or Not Reported0001001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SLE- PlaceboSLE- BranebrutinibpSS- PlacebopSS- BranebrutinibRA- PlaceboRA- BranebrutinibTotal
Asian - Non-Japanese — Asian - Non-Japanese0000022
Asian - Non-Japanese — Black or African American1300026
Asian - Non-Japanese — White26492159101
Asian - Non-Japanese — Not Reported0001012
Asian - Non-Japanese — American Indian or Alaska Native2600008
08

Study locations

81 sites
  • Local Institution - 0019
    Phoenix, Arizona 85032, United States
  • Local Institution - 0002
    Covina, California 91723, United States
  • Local Institution - 0024
    Encino, California 91436, United States
  • Local Institution - 0034
    San Diego, California 92108, United States
  • Local Institution - 0032
    Upland, California 91786, United States
  • Local Institution
    Brandon, Florida 33511, United States
  • Local Institution - 0062
    DeBary, Florida 32713, United States
  • Local Institution - 0035
    Hialeah, Florida 33016, United States
  • Local Institution
    Jacksonville, Florida 32209, United States
  • Local Institution - 0029
    Plantation, Florida 33324, United States
  • Local Institution - 0009
    Lawrenceville, Georgia 30046, United States
  • Local Institution - 0014
    Skokie, Illinois 60076, United States
  • Local Institution
    Evansville, Indiana 47715, United States
  • Local Institution - 0005
    Monroe, Louisiana 71203, United States
  • Local Institution - 0041
    Ann Arbor, Michigan 48109, United States
  • Local Institution - 0082
    Grand Blanc, Michigan 48439, United States
  • Local Institution - 0096
    Saint Louis, Missouri 63131, United States
  • Local Institution - 0040
    Saint Louis, Missouri 63141, United States
  • Local Institution - 0056
    Lincoln, Nebraska 68516, United States
  • Local Institution - 0007
    Las Vegas, Nevada 89119, United States
  • Local Institution
    Manhasset, New York 11030, United States
  • Local Institution
    New York, New York 10016, United States
  • Local Institution - 0008
    Charlotte, North Carolina 28204, United States
  • Local Institution - 0006
    Salisbury, North Carolina 28144, United States
  • Local Institution
    Minot, North Dakota 58701, United States
  • Local Institution - 0023
    Oklahoma City, Oklahoma 73103-2433, United States
  • Local Institution - 0022
    Oklahoma City, Oklahoma 79112, United States
  • Local Institution - 0010
    Duncansville, Pennsylvania 16635, United States
  • Local Institution - 0045
    Orangeburg, South Carolina 29118, United States
  • Local Institution - 0021
    Summerville, South Carolina 29486, United States
  • Local Institution - 0079
    Jackson, Tennessee 38305, United States
  • Local Institution - 0001
    Memphis, Tennessee 38119, United States
  • Local Institution - 0092
    Colleyville, Texas 76034, United States
  • Local Institution
    Dallas, Texas 75231, United States
  • Local Institution - 0063
    Houston, Texas 77084, United States
  • Local Institution - 0016
    Mesquite, Texas 75150, United States
  • Local Institution - 0030
    Plano, Texas 75024, United States
  • Local Institution - 0031
    San Antonio, Texas 78215, United States
  • Local Institution
    Waco, Texas 76710, United States
  • Local Institution - 0083
    Spokane, Washington 99204, United States
  • Local Institution - 0065
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1431FWO, Argentina
  • Local Institution - 0047
    San Miguel De Tucum, Tucuman T4000AXL, Argentina
  • Local Institution - 0066
    San Juan, J5402DIL, Argentina
  • Local Institution - 0064
    Gent, 9000, Belgium
  • Local Institution - 0069
    Leuven, 3000, Belgium
  • Local Institution - 0075
    Brest, 29609, France
  • Local Institution - 0070
    Marseille, 13003, France
  • Local Institution - 0067
    Montpellier Cedex 5, 34295, France
  • Local Institution - 0038
    Berlin, 10117, Germany
  • Local Institution - 0049
    Freiburg, 79106, Germany
  • Local Institution - 0074
    Herne, 44649, Germany
  • Local Institution - 0037
    Koln, 50937, Germany
  • Local Institution - 0051
    Munchen, 80336, Germany
  • Local Institution - 0060
    Guadalajara, Jalisco 44160, Mexico
  • Local Institution - 0042
    Guadalajara, Jalisco 44650, Mexico
  • Local Institution - 0113
    Zapopan, Jalisco 45070, Mexico
  • Local Institution - 0102
    Cuernavaca, Morelos 62290, Mexico
  • Local Institution - 0104
    Merida, Yucatan 97000, Mexico
  • Local Institution - 0114
    San Luis Potosi, 78200, Mexico
  • Local Institution - 0050
    San Luis Potosi, 78213, Mexico
  • Local Institution - 0059
    San Luis Potosi, 78240, Mexico
  • Local Institution - 0004
    Groningen, 9713 GZ, Netherlands
  • Local Institution - 0094
    Bialystok, 15-879, Poland
  • Local Institution - 0089
    Bydgoszcz, 85-065, Poland
  • Local Institution - 0072
    Bydgoszcz, 85-168, Poland
  • Local Institution - 0012
    Elblag, 82-300, Poland
  • Local Institution - 0073
    Elblag, 82-300, Poland
  • Local Institution - 0011
    Poznan, 60-773, Poland
  • Local Institution - 0091
    Torun, 87-100, Poland
  • Local Institution - 0017
    Warszawa, 00-660, Poland
  • Local Institution - 0033
    Warszawa, 02-691, Poland
  • Local Institution - 0101
    Warszawa, 02-793, Poland
  • Local Institution - 0026
    Warszawa, 03-291, Poland
  • Local Institution - 0028
    A Coru, 15006, Spain
  • Local Institution - 0036
    Barcelona, 08035, Spain
  • Local Institution - 0025
    Malaga, 29010, Spain
  • Local Institution - 0018
    Sevilla, 41010, Spain
  • Local Institution - 0061
    Valencia, 46010, Spain
  • Local Institution - 0076
    Leeds, LS7 4SA, United Kingdom
  • Local Institution - 0058
    London, SE1 9RT, United Kingdom
  • Local Institution - 0052
    Southampton, SO16 6YD, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2020 to primary completion in Dec 2022, 34 months.

Results were first posted in Jan 2024, 1 year 1 month after primary completion.

Of 60 phase 2 interventional studies under Autoimmune Diseases, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 100. This study's 34 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 28, 2019
First posted
Dec 5, 2019
StartActual
Jan 7, 2020
Primary completionActual
Dec 5, 2022
CompletionActual
Dec 5, 2022
Results first posted
Jan 16, 2024
Last update
Jan 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04186871
Responsible party
Sponsor
First posted
Dec 5, 2019
Start date
Jan 7, 2020
Primary completion
Dec 5, 2022
Completion
Dec 5, 2022
Results posted
Jan 16, 2024
Last update
Jan 16, 2024

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Branebrutinib · Abatacept

Start the discussion